Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Liabilities and Shareholders Equity (2024 - 2025)

Pelthos Therapeutics has reported Liabilities and Shareholders Equity over the past 2 years, most recently at $130.4 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $130.4 million for Q4 2025, up 9424.98% from a year ago — trailing twelve months through Dec 2025 was $258.6 million (up 2448.92% YoY), and the annual figure for FY2025 was $130.4 million, up 9424.98%.
  • Liabilities and Shareholders Equity for Q4 2025 was $130.4 million at Pelthos Therapeutics, up from $126.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for PTHS hit a ceiling of $130.4 million in Q4 2025 and a floor of $822850.0 in Q2 2025.